AtriCure CEO acquires 636 shares via ESPP

Q: What did AtriCure (ATRC) CEO Michael Carrel report in this Form 4?

Michael Carrel reported acquiring 636 shares of AtriCure common stock through the company’s 2018 Employee Stock Purchase Plan. This routine purchase increased his directly held shares to 779,134, reflecting ongoing participation in AtriCure’s employee equity programs.

Q: At what price were the new AtriCure (ATRC) shares acquired under the ESPP?

The 636 shares were acquired at an effective price of $23.78 per share. Under the Employee Stock Purchase Plan, this equals 85% of the $27.98 closing price of AtriCure common stock on June 30, 2026.

Q: What is the role of the AtriCure 2018 Employee Stock Purchase Plan in this Form 4?

The 2018 Employee Stock Purchase Plan enabled Michael Carrel to acquire 636 shares for the period ended June 30, 2026. The plan allows purchases at 85% of the closing stock price on the last trading day of the offering period.

Q: How are AtriCure (ATRC) shares held by Michael Carrel’s family reported?

The Form 4 lists indirect holdings as common stock held by his sibling, parents, and children. The filing states that Carrel disclaims beneficial ownership of these securities, except as to his pecuniary interest in them.

AtriCure, Inc. President and CEO Michael H. Carrel reported a new share acquisition through an employee purchase program.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AtriCure, Inc. President and CEO Michael H. Carrel reported a new share acquisition through an employee purchase program. On June 30, 2026, he acquired 636 shares of common stock directly at an effective price of $23.78 per share under AtriCure’s 2018 Employee Stock Purchase Plan.

These shares were purchased at 85% of the $27.98 closing price on June 30, 2026, as provided by the plan. After this transaction, Carrel directly holds 779,134 common shares. Additional indirect holdings are reported as shares held by his sibling, parents, and children, for which he disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

Grant/Award: 636 shares

Grant/Award 4 txns

Insider CARREL MICHAEL H

Role President, CEO, & Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	636	$23.78	$15K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 779,134 shares (Direct); Common Stock — 14,310 shares (Indirect, Held by reporting person's children); Common Stock — 2,250 shares (Indirect, Held by reporting person's parents); Common Stock — 1,000 shares (Indirect, Held by reporting person's sibling)

Footnotes (3)

F1. Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
F2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.
F3. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.

Key Figures

ESPP shares acquired: 636 shares Effective ESPP purchase price: $23.78 per share Closing price reference: $27.98 per share +5 more

8 metrics

ESPP shares acquired 636 shares Common stock acquired on June 30, 2026 under 2018 ESPP

Effective ESPP purchase price $23.78 per share Price for 636 shares acquired June 30, 2026

Closing price reference $27.98 per share AtriCure common stock closing price on June 30, 2026

Discount rate 85% ESPP purchase percentage of June 30, 2026 closing price

Direct shares after transaction 779,134 shares Common stock directly held by Michael Carrel after ESPP acquisition

Indirect sibling-held shares 1,000 shares Common stock held by reporting person’s sibling

Indirect parents-held shares 2,250 shares Common stock held by reporting person’s parents

Indirect children-held shares 14,310 shares Common stock held by reporting person’s children

Key Terms

2018 Employee Stock Purchase Plan, beneficial ownership, pecuniary interest, grant, award, or other acquisition

4 terms

2018 Employee Stock Purchase Plan financial

"Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026."

beneficial ownership financial

"The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein."

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AtriCure (ATRC) CEO Michael Carrel report in this Form 4?

Michael Carrel reported acquiring 636 shares of AtriCure common stock through the company’s 2018 Employee Stock Purchase Plan. This routine purchase increased his directly held shares to 779,134, reflecting ongoing participation in AtriCure’s employee equity programs.

At what price were the new AtriCure (ATRC) shares acquired under the ESPP?

The 636 shares were acquired at an effective price of $23.78 per share. Under the Employee Stock Purchase Plan, this equals 85% of the $27.98 closing price of AtriCure common stock on June 30, 2026.

How many AtriCure (ATRC) shares does Michael Carrel hold after this filing?

Following the ESPP acquisition, Michael Carrel directly holds 779,134 shares of AtriCure common stock. The Form 4 also reports indirect holdings in accounts for his sibling, parents, and children, with a disclaimer of beneficial ownership except for any pecuniary interest.

What is the role of the AtriCure 2018 Employee Stock Purchase Plan in this Form 4?

The 2018 Employee Stock Purchase Plan enabled Michael Carrel to acquire 636 shares for the period ended June 30, 2026. The plan allows purchases at 85% of the closing stock price on the last trading day of the offering period.

How are AtriCure (ATRC) shares held by Michael Carrel’s family reported?

The Form 4 lists indirect holdings as common stock held by his sibling, parents, and children. The filing states that Carrel disclaims beneficial ownership of these securities, except as to his pecuniary interest in them.

Is this AtriCure (ATRC) Form 4 an open-market stock purchase?

No. The 636-share acquisition is reported with code A as a grant, award, or other acquisition under an Employee Stock Purchase Plan, not as an open-market trade. Pricing is set by the ESPP formula tied to the June 30, 2026 closing price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/02/2026 - 09:06 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARREL MICHAEL H

(Last)

(First)

(Middle)

7555 INNOVATION WAY

(Street)

MASON

OHIO

45040-9695

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, CEO, & Director

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		A		636⁽¹⁾	A	$23.78⁽²⁾	779,134	D
Common Stock								14,310	I	Held by reporting person's children⁽³⁾
Common Stock								2,250	I	Held by reporting person's parents⁽³⁾
Common Stock								1,000	I	Held by reporting person's sibling⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

3. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for Michael H. Carrel	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR